Fig. 2: Forecasted patient trajectories under different myeloma treatments.
From: Predicting progression events in multiple myeloma from routine blood work
Forecasted patient trajectories for three individual patients undergoing different treatments. The patients were treated with (a) Bortezomib-based, (b) Carfilzomib-based, and (c) IMIDs-based. The forecasting model utilized the initial seven follow-ups, equivalent to 21 months of clinical data, to predict the subsequent five follow-ups, which span an additional 15 months. Dashed lines and crosses represent the forecasts, while circles denote actual observations. Gray sleeves illustrate the 95% confidence interval of the distribution of forecasted trajectories.
